APO-Pemetrexed pemetrexed 500 mg (as disodium) powder for injection vial

Kraj: Australia

Język: angielski

Źródło: Department of Health (Therapeutic Goods Administration)

Składnik aktywny:

pemetrexed disodium hemipentahydrate, Quantity: 604 mg (Equivalent: pemetrexed, Qty 500 mg)

Dostępny od:

Arrotex Pharmaceuticals Pty Ltd

INN (International Nazwa):

pemetrexed disodium hemipentahydrate

Forma farmaceutyczna:

Injection, powder for

Skład:

Excipient Ingredients: sodium hydroxide; hydrochloric acid; mannitol

Droga podania:

Intravenous Infusion

Sztuk w opakowaniu:

1

Typ recepty:

(S4) Prescription Only Medicine

Wskazania:

Malignant Pleural Mesothelioma,Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,Non-Small Cell Lung Cancer (NSCLC),Pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology.,Pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Podsumowanie produktu:

Visual Identification: White to either light yellow or green-yellow powder.; Container Type: Vial; Container Material: Glass; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status autoryzacji:

Registered

Data autoryzacji:

2014-09-04